BOSTON, May 13, 2019 /PRNewswire/ -- Proteostasis
Therapeutics, Inc. (NASDAQ:PTI), a clinical stage biopharmaceutical
company dedicated to the discovery and development of
groundbreaking therapies to treat cystic fibrosis (CF) and other
diseases caused by dysfunctional protein processing, today
announced that Badrul A. Chowdhury,
M.D., Ph.D., has been appointed to the Company's Board of
Directors. Dr. Chowdhury is Senior Vice President and Chief
Physician-Scientist, Respiratory Inflammation and Autoimmunity
(RIA) Late Stage, R&D Biopharmaceuticals, at AstraZeneca.
He was previously Director of the Division of Pulmonary, Allergy,
and Rheumatology Products at the U.S. Food and Drug
Administration's (FDA) Center for Drug Evaluation and Research
(CDER).
"Dr. Chowdhury has deep expertise as a regulatory strategist,
including having presided over the FDA approvals of the current
standard-of-care CFTR modulators. With a broad view across
many diseases, including CF, his counsel will be invaluable to PTI
as we advance our CF pipeline toward launching our Phase 3 program
in mid-2020. We are thrilled to welcome him to the PTI board of
directors," said Meenu Chhabra,
President and Chief Executive Officer of Proteostasis.
"With its next generation CFTR modulators, Proteostasis has
demonstrated the promise of becoming a highly-credible new entrant
into the CF marketplace," commented Dr. Chowdhury. "The
CF community has a resounding need for more options to address
issues that include patient access, tolerability and durability of
treatment. I look forward to contributing as a director to PTI's
mission of bringing more treatment options to patients with cystic
fibrosis."
Dr. Chowdhury practiced medicine for more than a decade and has
more than two decades of regulatory leadership experience. Prior to
joining AstraZeneca in April 2018,
Dr. Chowdhury served at the FDA for 21 years, where he held
numerous leadership roles. His previous roles at the FDA include
Medical Team Leader, Division of Pulmonary and Allergy Drug
Products, CDER, and Medical Officer, Division of Pulmonary Drug
Products, CDER. Dr. Chowdhury has a M.B., B.S. in Medicine from
University of Dhaka, Dhaka Medical
College, Bangladesh, and a Ph.D.
in Immunology from Memorial University of
Newfoundland, Canada. He completed his residency training in
Internal Medicine at the Wayne State
University School of Medicine, Detroit, Michigan, and a fellowship in Allergy
and Immunology at the National Institutes of Health's, National
Institute of Allergy and Infectious Diseases, Bethesda, Maryland, and is double board
certified in Internal Medicine and Allergy and Immunology.
About Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. is a clinical stage
biopharmaceutical company developing small molecule therapeutics to
treat cystic fibrosis and other diseases caused by dysfunctional
protein processing. Headquartered in Boston, MA, the Proteostasis Therapeutics team
focuses on identifying therapies that restore protein function. For
more information, visit www.proteostasis.com.
Safe Harbor
To the extent that statements in this release are not historical
facts, they are forward-looking statements reflecting the current
beliefs and expectations of management made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. Words such as "aim," "may," "will," "expect,"
"anticipate," "estimate," "intend," and similar expressions (as
well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. Examples of forward-looking
statements made in this release include, without limitation,
statements regarding the potential of our proprietary combination
therapies for the treatment of CF, the potential benefit to
patients of our proprietary combination therapies, expected
presentations and expected timing of the initiation of, patient
enrollment in, data from, the completion of, our clinical studies
and cohorts for our clinical programs, including our planned Phase
3 program, and our expectations regarding our new board
member. Forward-looking statements made in this release
involve substantial risks and uncertainties that could cause actual
results to differ materially from those expressed or implied by the
forward-looking statements, and we, therefore cannot assure you
that our plans, intentions, expectations or strategies will be
attained or achieved. Such risks and uncertainties include,
without limitation, the possibility final or future results from
our drug candidate trials (including, without limitation, longer
duration studies) do not achieve positive results or are materially
and negatively different from or not indicative of the preliminary
results reported by the Company (noting that these results are
based on a small number of patients and small data set),
uncertainties inherent in the execution and completion of clinical
trials (including, without limitation, the possibility that FDA
comments delay, change or do not permit trial commencement, or
intended label, or the FDA requires us to run cohorts sequentially
or conduct additional cohorts or pre-clinical or clinical studies),
in the enrollment of CF patients in our clinical trials in a
competitive clinical environment, in the timing of availability of
trial data, in the results of the clinical trials, in possible
adverse events from our trials, in the actions of regulatory
agencies, in the endorsement, if any, by therapeutic development
arms of CF patient advocacy groups (and the maintenance thereof),
and those set forth in our Annual Report on Form 10-K for the year
ended December 31, 2018 and our other
SEC filings. We assume no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
CONTACTS:
Investors:
David Pitts
/ Claudia Styslinger
Argot Partners
212.600.1902
david@argotpartners.com / claudia@argotpartners.com
Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com
View original
content:http://www.prnewswire.com/news-releases/proteostasis-therapeutics-appoints-dr-badrul-chowdhury-former-fda-director-of-pulmonology-allergy-and-rheumatology-to-board-of-directors-300848640.html
SOURCE Proteostasis Therapeutics, Inc.